Stockscreener 앱 받기
3.12
0.32%
-0.010
시간 외 거래:
3.12
전일 마감가:
$3.13
열려 있는:
$3.13
하루 거래량:
6.79M
Relative Volume:
0.63
시가총액:
$803.19M
수익:
$403.14M
순이익/손실:
$-22.68M
주가수익비율:
-14.89
EPS:
-0.2095
순현금흐름:
$-13.09M
1주 성능:
-0.32%
1개월 성능:
+63.35%
6개월 성능:
-21.01%
1년 성능:
+294.79%
1일 변동 폭
$3.12
$3.13
1주일 범위
$3.12
$3.14
52주 변동 폭
$0.792
$4.175
Esperion Therapeutics Inc Stock (ESPR) Company Profile
명칭
Esperion Therapeutics Inc
전화
734-887-3903
주소
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
3.12 | 805.76M | 403.14M | -22.68M | -13.09M | -0.2095 |
TAK
Takeda Pharmaceutical Co Adr
|
15.87 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.24 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.61 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.23 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
578.43 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-25 | 개시 | Piper Sandler | Overweight |
| 2024-12-18 | 개시 | Goldman | Neutral |
| 2024-12-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-06-20 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-08-01 | 업그레이드 | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2023-03-16 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-03-16 | 다운그레이드 | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | 재개 | BofA Securities | Neutral |
| 2023-02-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-03-10 | 개시 | H.C. Wainwright | Buy |
| 2021-10-19 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-02-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-02-09 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-01-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-11-10 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | 재개 | JP Morgan | Underweight |
| 2020-08-11 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | 재개 | BofA/Merrill | Buy |
| 2020-03-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-02-24 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-09-16 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-05-29 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-05-06 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-03-13 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2019-01-07 | 재확인 | Needham | Strong Buy |
| 2018-12-13 | 개시 | Goldman | Sell |
| 2018-10-29 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | 개시 | BTIG Research | Buy |
| 2018-08-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-07-11 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-05-02 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
모두보기
Esperion Therapeutics Inc 주식(ESPR)의 최신 뉴스
Trial tests cholesterol drug in kids with inherited high cholesterol - Stock Titan
ESPR Stock Price, Quote & Chart | ESPERION THERAPEUTICS INC (NASDAQ:ESPR) - ChartMill
Esperion Therapeutics stock (US2964331002): buyout by Archimed and fresh earnings put focus on futur - AD HOC NEWS
Epilogue On Esperion Therapeutics Stock (NASDAQ:ESPR) - Seeking Alpha
ETFs Investing in Esperion Therapeutics, Inc. Stocks - TradingView
Esperion Therapeutics (ESPR) price target decreased by 59.91% to 2.97 - MSN
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Sahm
Esperion Therapeutics estimates U.S. heart failure costs at 46B dollars a year, urges therapy optimization - Traders Union
Esperion Therapeutics stock (US2964331002): Archimed acquisition deal closes chapter on independent - AD HOC NEWS
ESPR Stock Surges 44% in a Month: Here's What You Need to Know - sharewise.com
Drugmaker Esperion gives new hires 260,000 stock units to join - Stock Titan
Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026 - The Manila Times
Esperion Announces Two New Analyses Supporting Bempedoic - GlobeNewswire
New cholesterol data in kids and statin-intolerant adults at EAS 2026 - Stock Titan
Needham Maintains Esperion Therapeutics(ESPR.US) With Hold Rating - Moomoo
Esperion Therapeutics(ESPR) Stock Options Chain | Quotes & News - Moomoo
TradingKey - TradingKey
Esperion Therapeutics’ 10-Q Forward-Looking Statements Highlight Significant Uncertainty and Investor Risk - The Globe and Mail
Esperion Therapeutics (ESPR) Q4 Profit Swing Challenges Bearish Earnings Narratives - Sahm
Esperion Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Esperion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Buyout values Esperion (NASDAQ: ESPR) at $3.16 in cash plus CVR - Stock Titan
Hypercholesterolemia Treatment Market is expected to Hit US$ - openPR.com
Esperion Therapeutics Q1 2026 earnings preview - MSN
United StatesGoodwin Advises Esperion On $1.1 Billion Acquisition By ARCHIMED - Mondaq
Halper Sadeh LLC is Investigating Whether SILA, ESPR, CRBG, EQH are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
MSN Money - MSN
SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--ESPR, SILA, CRBG, and EQH - Sahm
BIOG's investee Esperion bought by ArchiMed for USD1 billion - marketscreener.com
Esperion (ESPR) was downgraded to a Hold Rating at Needham - The Globe and Mail
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Na - ChartMill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq - GlobeNewswire Inc.
Needham downgrades Esperion Therapeutics (ESPR) - MSN
BioPharma Credit to Finance Archimed's Purchase of Biotech Growth Trust's Esperion Therapeutics - Moomoo
Esperion to be acquired by ARCHIMED - The Pharma Letter
PRN_FinancialWrapper - FinancialContent
Esperion Therapeutics Cut to Hold From Buy by Needham - Moomoo
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc.ESPR - The AI Journal
Jefferies Maintains Esperion Therapeutics(ESPR.US) With Hold Rating, Maintains Target Price $3.28 - Moomoo
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Hold Rating, Maintains Target Price $3.16 - Moomoo
Jefferies Downgrades Esperion Therapeutics to Hold From Buy, Adjusts Price Target to $3.28 From $5 - marketscreener.com
Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - FinancialContent
ESPR Jumps On ARCHIMED Buyout Deal And Nasdaq Exit Plan - StocksToTrade
Penny Stocks To Watch TodayMay 2nd - MarketBeat
ESPR Jumps As Esperion Agrees To $1.1B Archimed Buyout - timothysykes.com
A Quick Look at Today's Ratings for Esperion Therapeutics(ESPR.US), With a Forecast Between $3.16 to $3.28 - Moomoo
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Esperion Therapeutics, Inc. $ESPR is AIGH Capital Management LLC's 10th Largest Position - MarketBeat
HC Wainwright & Co. downgrades Esperion Therapeutics (ESPR) - MSN
Crude Oil Down 3%; Chevron Posts Mixed Q1 Results - Benzinga
Sidley, Goodwin Lead $1.1B Take-Private Deal For Esperion - Law360
Esperion Therapeutics Inc (ESPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Esperion Therapeutics Inc 주식 (ESPR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Koenig Sheldon L. | President and CEO |
Mar 17 '26 |
Sale |
2.72 |
25,578 |
69,547 |
2,172,699 |
| Halladay Benjamin | Chief Financial Officer |
Mar 17 '26 |
Sale |
2.71 |
6,424 |
17,377 |
713,602 |
5.02%
5.78%
자본화:
|
볼륨(24시간):